Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 2Thoracic 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Pancreatic Neoplasms 1Melanoma 1Lung Neoplasms 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Breast Neoplasms 1

Interventions

pembrolizumab 33Paclitaxel 27Cyclophosphamide 25Carboplatin 23olaparib 21Fulvestrant 15fludarabine 14Trastuzumab 14aldesleukin 13Docetaxel 13Early Intervention, Educational 12Surveys and Questionnaires 11veliparib 10palbociclib 10Methods 10Gemcitabine 10Blood Specimen Collection 10Nivolumab 9Flow Cytometry 9Biopsy 9Bevacizumab 9sargramostim 8niraparib 7liposomal doxorubicin 7Therapeutics 7Taxes 7Standard of Care 7Psychiatric Rehabilitation 7Magnetic Resonance Spectroscopy 7talazoparib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Neoplasms × parsaclisib × Gynecologic × Clear all
NCT02646748 2022-03-31

Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors

Incyte Corporation

Phase 1 Completed
159 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Renal Cell, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Pancreatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡